

Product Information

Anti-Human IgG (whole molecule)–Peroxidase produced in rabbit, IgG fraction of antiserum

Catalog Number **A8792**

Product Description

Antiserum is produced in rabbit using purified human IgG as the immunogen. Whole antiserum is fractionated and then further purified by ion exchange chromatography to provide the IgG fraction of antiserum. This fraction is essentially free of other rabbit serum proteins. Rabbit anti-human IgG is then conjugated to peroxidase by protein cross-linking with 0.2% glutaraldehyde.

Specificity of Anti-Human IgG (whole molecule)-Peroxidase is determined by immunoelectrophoresis (IEP) versus normal human serum and human IgG.

Identity and purity of the antibody is established by immunoelectrophoresis prior to conjugation. Electrophoresis of the product followed by diffusion versus the anti-rabbit IgG and the anti-rabbit whole serum results in single arcs of precipitation in the γ -region.

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 0.01% thimerosal as a preservative.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Store at $-20\text{ }^{\circ}\text{C}$ for long term use. For continuous use, the product may be stored at $2\text{-}8\text{ }^{\circ}\text{C}$ for up to one month. For extended storage, the solution should be frozen in working aliquots at $-20\text{ }^{\circ}\text{C}$. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use.

Product Profile

Direct ELISA: 40,000 - 1:50,000

We are now reporting lot specific information as a titer by direct ELISA rather than as a working dilution. Titer is defined as the dilution of conjugate sufficient to give a change in absorbance of 1.0 at 450 nm after 30 minutes of substrate conversion at $25\text{ }^{\circ}\text{C}$.¹ Microtiter plates are coated with purified human IgG at a concentration of $5\text{ }\mu\text{g/ml}$ in 0.05 M carbonate-bicarbonate buffer, pH 9.6. Carbonate-Bicarbonate Buffer capsules are available as Catalog Number C3041.

Substrate: *o*-Phenylenediamine Dihydrochloride (OPD), Catalog Number P8287, 0.4 mg/ml in 0.05 M phosphate-citrate buffer, pH 5.0 containing 0.03% sodium perborate. Phosphate-Citrate Buffer with Sodium Perborate capsules are available as Catalog Number P4922.

Dot Blot: a minimum dilution of 1:6,000 was determined in a direct assay using 40 ng human IgG/dot.

Immunoblotting: a minimum dilution of 1:80,000 was determined in a direct chemiluminescence assay using 10 ng human IgG/dot. Luminol plus enhancer was used as substrate.

Immunohistochemistry: a minimum dilution of 1:150 was determined by direct staining of formalin-fixed, paraffin-embedded human tonsil sections.

Note: Working dilutions should be determined by titration assay. Due to differences in assay systems, these titers may not reflect the user's actual working dilution.

Molar Ratio (IgG:Peroxidase): 0.8 to 1.5

Reference

1. Voller, A., et al., Bulletin WHO, **53**, 55 (1976).

MG,KAA,PHC 06/09-1